PURPOSE: A phase I/II trial was performed to evaluate the safety and immunogenicity of a novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides for glioma-associated antigen (GAA) epitopes and administration of polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in HLA-A2(+) patients with recurrent malignant gliomas. GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100. PATIENTS AND METHODS: Twenty-two patients (13 with glioblastoma multiforme [GBM], five with anaplastic astrocytoma [AA], three with anaplastic oligodendroglioma [AO], and one with anaplastic oligoastrocytoma [AOA]) received at least one vaccination, and 19 patients received at least four vaccinations at two αDC1 dose levels (1 × or 3 × 10(7)/dose) at 2-week intervals intranodally. Patients also received twice weekly intramuscular injections of 20 μg/kg poly-ICLC. Patients who demonstrated positive radiologic response or stable disease without major adverse events were allowed to receive booster vaccines. T-lymphocyte responses against GAA epitopes were assessed by enzyme-linked immunosorbent spot and HLA-tetramer assays. RESULTS: The regimen was well-tolerated. The first four vaccines induced positive immune responses against at least one of the vaccination-targeted GAAs in peripheral blood mononuclear cells in 58% of patients. Peripheral blood samples demonstrated significant upregulation of type 1 cytokines and chemokines, including interferon-α and CXCL10. Nine (four GBM, two AA, two AO, and one AOA) achieved progression-free status lasting at least 12 months. One patient with recurrent GBM demonstrated sustained complete response. IL-12 production levels by αDC1 positively correlated with time to progression. CONCLUSION: These data support safety, immunogenicity, and preliminary clinical activity of poly-ICLC-boosted αDC1-based vaccines.
PURPOSE: A phase I/II trial was performed to evaluate the safety and immunogenicity of a novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides for glioma-associated antigen (GAA) epitopes and administration of polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in HLA-A2(+) patients with recurrent malignant gliomas. GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100. PATIENTS AND METHODS: Twenty-two patients (13 with glioblastoma multiforme [GBM], five with anaplastic astrocytoma [AA], three with anaplastic oligodendroglioma [AO], and one with anaplastic oligoastrocytoma [AOA]) received at least one vaccination, and 19 patients received at least four vaccinations at two αDC1 dose levels (1 × or 3 × 10(7)/dose) at 2-week intervals intranodally. Patients also received twice weekly intramuscular injections of 20 μg/kg poly-ICLC. Patients who demonstrated positive radiologic response or stable disease without major adverse events were allowed to receive booster vaccines. T-lymphocyte responses against GAA epitopes were assessed by enzyme-linked immunosorbent spot and HLA-tetramer assays. RESULTS: The regimen was well-tolerated. The first four vaccines induced positive immune responses against at least one of the vaccination-targeted GAAs in peripheral blood mononuclear cells in 58% of patients. Peripheral blood samples demonstrated significant upregulation of type 1 cytokines and chemokines, including interferon-α and CXCL10. Nine (four GBM, two AA, two AO, and one AOA) achieved progression-free status lasting at least 12 months. One patient with recurrent GBM demonstrated sustained complete response. IL-12 production levels by αDC1 positively correlated with time to progression. CONCLUSION: These data support safety, immunogenicity, and preliminary clinical activity of poly-ICLC-boosted αDC1-based vaccines.
Authors: Craig L Slingluff; Gina R Petroni; Walter Olson; Andrea Czarkowski; William W Grosh; Mark Smolkin; Kimberly A Chianese-Bullock; Patrice Y Neese; Donna H Deacon; Carmel Nail; Priscilla Merrill; Robyn Fink; James W Patterson; Patrice K Rehm Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544
Authors: Xinmei Zhu; Beth A Fallert-Junecko; Mitsugu Fujita; Ryo Ueda; Gary Kohanbash; Edward R Kastenhuber; Heather A McDonald; Yan Liu; Pawel Kalinski; Todd A Reinhart; Andres M Salazar; Hideho Okada Journal: Cancer Immunol Immunother Date: 2010-06-12 Impact factor: 6.968
Authors: Junichi Eguchi; Manabu Hatano; Fumihiko Nishimura; Xinmei Zhu; Jill E Dusak; Hidemitsu Sato; Ian F Pollack; Walter J Storkus; Hideho Okada Journal: Cancer Res Date: 2006-06-01 Impact factor: 12.701
Authors: Fumiyoshi Okano; Walter J Storkus; William H Chambers; Ian F Pollack; Hideho Okada Journal: Clin Cancer Res Date: 2002-09 Impact factor: 12.531
Authors: Nicholas Butowski; Susan M Chang; Larry Junck; Lisa M DeAngelis; Lauren Abrey; Karen Fink; Tim Cloughesy; Kathleen R Lamborn; Andres M Salazar; Michael D Prados Journal: J Neurooncol Date: 2008-09-17 Impact factor: 4.130
Authors: Mitsugu Fujita; Xinmei Zhu; Ryo Ueda; Kotaro Sasaki; Gary Kohanbash; Edward R Kastenhuber; Heather A McDonald; Gregory A Gibson; Simon C Watkins; Ravikumar Muthuswamy; Pawel Kalinski; Hideho Okada Journal: Cancer Res Date: 2009-02-03 Impact factor: 12.701
Authors: Yohei Mineharu; Gwendalyn D King; A K M G Muhammad; Serguei Bannykh; Kurt M Kroeger; Chunyan Liu; Pedro R Lowenstein; Maria G Castro Journal: Clin Cancer Res Date: 2011-06-01 Impact factor: 12.531
Authors: Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531